search
Back to results

Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS) (QPL-MDS)

Primary Purpose

Myelodysplastic Syndromes

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Question prompt list (QPL)
Education brochure of Groupe Français des Myélodysplasies
Sponsored by
Institut Paoli-Calmettes
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Myelodysplastic Syndromes

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients newly referred for a MDS in one of the participating centres
  • Older than 18
  • Able to answer a self-administered questionnaire
  • Having signed an informed consent
  • affiliated to the French Social Security System

Exclusion Criteria:

  • emergency,patients deprived of liberty or placed under the authority of a tutor

Sites / Locations

  • Chu GrenobleRecruiting
  • Institut Paoli-CalmettesRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

Control group

General QPL group

Targeted QPL group

Arm Description

Patients will receive only the education brochure of GFM

Patients will receive the brochure and the newly developed QPL (general version)

Patients will receive the brochure and the newly developed QPL (general version)

Outcomes

Primary Outcome Measures

Patients having discussed as they wished about the prognosis of their MDS in the next medical consultation
The discussion about prognosis will be collected through the audiotaping of the consultation.

Secondary Outcome Measures

number of questions and concerns expressed in each content category covered by the QPL (including prognosis)
Data collected through the audiotaping of the consultation
Duration of the recorded consultation
Data collected through the audiotaping of the consultation
Quality of life
Questionnaire
Anxiety
Questionnaire
Satisfaction with the provided information
Questionnaire

Full Information

First Posted
May 18, 2016
Last Updated
September 1, 2017
Sponsor
Institut Paoli-Calmettes
search

1. Study Identification

Unique Protocol Identification Number
NCT02781441
Brief Title
Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS)
Acronym
QPL-MDS
Official Title
Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2017
Overall Recruitment Status
Unknown status
Study Start Date
April 2016 (undefined)
Primary Completion Date
April 2018 (Anticipated)
Study Completion Date
September 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut Paoli-Calmettes

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
MDS are a diverse group of hematopoietic malignancies, which mainly occur in patients over 75 years of age. Incidence rate in 2012 in France was more than 6 cases per 100 000 person-years. MDS are characterized by ineffective haematopoiesis causing cytopenia, and by leukemic transformation. The disease is heterogeneous, its pathophysiology complex and clinical evolution variable.The few data available on MDS patients show how difficult it is to understand MDS, its prognosis and the reasons for prescribing or not some treatments. In the context of a highly complex potentially lethal disease such as MDS, it is of utmost importance to optimize the information conveyed to patients. Particularly, 70.5% of MDS patients surveyed in our developmental study would have preferred more information about prognosis at diagnosis disclosure. A simple intervention based on the use of a question prompt list (QPL), would greatly improve the information process by helping patients to express their main concerns at their medical consultations. Cultural differences may exist in the appraisal of QPLs and QPLs have not yet been widely used in France. However, in line with the previous results available in the literature and in a context a priori favourable to the use of such an instrument, the investigators hypothesise that use of a QPL will increase MDS patients' expressions of concerns and questions at their medical consultations. Particularly the investigators assume that the discussion about prognosis will be facilitated, without increasing anxiety because patients remain free to ask or not for such information. The use of QPLs would also be a way to limit social inequalities related to insufficient information and to encourage patient-doctor communication and meeting of patient preferences which could lead to better health outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myelodysplastic Syndromes

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
140 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control group
Arm Type
Active Comparator
Arm Description
Patients will receive only the education brochure of GFM
Arm Title
General QPL group
Arm Type
Experimental
Arm Description
Patients will receive the brochure and the newly developed QPL (general version)
Arm Title
Targeted QPL group
Arm Type
Experimental
Arm Description
Patients will receive the brochure and the newly developed QPL (general version)
Intervention Type
Behavioral
Intervention Name(s)
Question prompt list (QPL)
Intervention Type
Behavioral
Intervention Name(s)
Education brochure of Groupe Français des Myélodysplasies
Primary Outcome Measure Information:
Title
Patients having discussed as they wished about the prognosis of their MDS in the next medical consultation
Description
The discussion about prognosis will be collected through the audiotaping of the consultation.
Time Frame
17 months
Secondary Outcome Measure Information:
Title
number of questions and concerns expressed in each content category covered by the QPL (including prognosis)
Description
Data collected through the audiotaping of the consultation
Time Frame
17 months
Title
Duration of the recorded consultation
Description
Data collected through the audiotaping of the consultation
Time Frame
17 months
Title
Quality of life
Description
Questionnaire
Time Frame
17 months
Title
Anxiety
Description
Questionnaire
Time Frame
17 months
Title
Satisfaction with the provided information
Description
Questionnaire
Time Frame
17 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients newly referred for a MDS in one of the participating centres Older than 18 Able to answer a self-administered questionnaire Having signed an informed consent affiliated to the French Social Security System Exclusion Criteria: emergency,patients deprived of liberty or placed under the authority of a tutor
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dominique GENRE, MD
Phone
0033491223778
Email
drci.up@ipc.unicancer.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Jihane PAKRADOUNI, PharmD PhD
Phone
0033491223778
Email
drci.up@ipc.unicancer.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jérôme Rey, MD
Organizational Affiliation
Institut Paoli-Calmettes
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chu Grenoble
City
Grenoble
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sophe PARK, MD,PhD
Email
spark@chu-grenoble.fr
Facility Name
Institut Paoli-Calmettes
City
Marseille
ZIP/Postal Code
13009
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jérôme REY, MD
Phone
0033491223696
First Name & Middle Initial & Last Name & Degree
Jihane PAKRADOUNI, PharmD PhD
Phone
0033491223778
Email
drci.up@ipc.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Norbert VEY, MD
First Name & Middle Initial & Last Name & Degree
Bilal MOHTY, MD
First Name & Middle Initial & Last Name & Degree
Aude CHARBONNIER, MD
First Name & Middle Initial & Last Name & Degree
Jérôme REY, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS)

We'll reach out to this number within 24 hrs